Agile Therapeutics(US:AGRX)2023-08-09 16:34Financial Performance - Net revenue for Q2 2023 was $5.5 million, a 44% increase compared to $3.8 million in Q1 2023 [16] - OPEX for Q2 2023 was $8.3 million, a 2% decrease compared to $8.5 million in Q1 2023 [16] - Net revenue YTD through June 30, 2023, was $9.3 million, a 140% increase compared to $3.9 million through June 30, 2022 [16] - OPEX YTD through June 30, 2023, was $16.8 million, a 38% decrease compared to $27.1 million through June 30, 2022 [16] - Q2 2023 net revenue increased by 159% to $5.5 million compared to $2.1 million in Q2 2022 [17] - Q2 2023 OPEX decreased by 26% to $8.3 million compared to $11.3 million in Q2 2022 [17] - The company expects net revenue for 2023 to be $25-$30 million [10, 17, 23] Business Outlook - The company aims to build a capital-efficient business that can generate sustainable growth and positive cash flow [23]